The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.
Horsham, PA (Vocus) August 26, 2009 -- The Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop from October 7-9, 2009 in Bethesda, MD.
Progression-Free Survival (PFS) endpoints are increasingly used for evaluation and approval of oncology drugs. Representatives from FDA, the National Cancer Institute (NCI), and PhRMA will present their perspectives on clinical, radiological, and statistical evaluation of progression-free survival. Sessions will include:
- Clinical Assessment of Progression-Free Survival (PFS)
- Radiological Evaluation of Progression-Free Survival (PFS)
- Criteria for Determination of Progression
- Statistical Evaluation of Progression-Free Survival- Role and Design of Independent Review
- Statistical Evaluation of Progression-Free Survival--Handling Missing/Censored Observations
- Statistical Evaluation of Progression-Free Survival--Analysis of Progression-Free Survival
- Regulatory Considerations
Richard Pazdur, MD, Director, Office of Oncology Drug Products, CDER, FDA, will deliver the keynote address. In addition to his experience as a regulatory expert at FDA, Dr. Pazdur has distinguished himself in clinical and academic oncology. Click here for complete bio.
In addition, two tutorials will be held on October 7:
- Time to Event Analysis for Non-Statisticians
- Statistical Methods for Interval Censored Data Analyses
to register for the Progression-Free Survival Oncology Workshop.
About the Drug Information Association (DIA):
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.
Read the full story at http://www.prweb.com/releases/2009/08/prweb2796274.htm.
Related medicine news :1
Copyright©2009 Vocus, Inc.
All rights reserved
. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation 2
. Advanced lung cancer patients see improved, progression-free survival3
. Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer4
. Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia5
. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men6
. Survival differences by race most apparent in advanced stages of breast cancer7
. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival8
. Human C-reactive protein regulates myeloma tumor cell growth and survival9
. Mediterranean Diet May Boost Alzheimers Survival10
. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows11
. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival